• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23982 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Penn Medicine Center for Evidence-based Practice (CEP) Public health preparedness for mass gatherings
2024     NIHR Health Technology Assessment programme Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Ketamine for adults with substance use disorders
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: COVID-19 - optimal use of parmacological treatments]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: access to innovations in health and social services - financing and decision-making]
2024     Scottish Health Technologies Group (SHTG) Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Ketorolac for renal colic
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: overview – comparison, based on health profile, of the use of primary care medical services by persons registered with a family physician and those who are not]
2024     Swiss Federal Office of Public Health (FOPH) Trikafta® for the treatment of patients with cystic fibrosis: an exploratory economic evaluation
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical and instrumental swallowing assessments for dysphagia
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Magnetic resonance neurography in peripheral neuropathy or plexopathy]
2024     Center for Drug Evaluation (CDE) [Health Technology Assessment Report : Opdivo (gastric cancer - GC)]
2024     Scottish Health Technologies Group (SHTG) Volatile capture technologies
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Timing of antibiotic therapy for neisseria gonorrhoeae infection
2024     NIHR Health Technology Assessment programme Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT
2024     Scottish Health Technologies Group (SHTG) Digital cancer prehabilitation
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Intra-articular hyaluronic acid for osteoarthritis of the hip, shoulder, and ankle
2024     NIHR Health Technology Assessment programme Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT
2024     Scottish Health Technologies Group (SHTG) Clopidogrel genotype testing after ischaemic stroke or transient ischaemic attack (TIA) - SHTG Assessment
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Aerosol therapy with inhalers during mechanical ventilation
2024     National Institute for Health and Care Excellence (NICE) Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension. NICE technology appraisal guidance 1009
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Opioid-sparing effects of IV acetaminophen for patients undergoing surgery
2024     National Institute for Health and Care Excellence (NICE) Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments. NICE technology appraisal guidance 1008
2024     Penn Medicine Center for Evidence-based Practice (CEP) Indications for urinary catheterization in sedated patients
2024     NIHR Health Technology Assessment programme Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)
2024     HTA South [Artificial intelligence in breast cancer screening with mammography]
2024     National Institute for Health and Care Excellence (NICE) Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. NICE technology appraisal guidance 1007
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Partially hydrolyzed formula to prevent cow’s milk allergy]
2024     Center for Drug Evaluation (CDE) [HTA for Medical Device: Metallic biliary stents (Rapid HTA report)]
2023     WorkSafeBC Cold plunges as treatment for concussions
2023     WorkSafeBC The effect of pepper spray on human health
2023     HTA South [Focused ultrasound treatment for tremor]
2023     WorkSafeBC Koebner phenomenon in connective tissue
2023     Adelaide Health Technology Assessment (AHTA) Newborn bloodspot screening for sickle cell disease
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Optune - for the treatment of adult patients with newly diagnosed glioblastoma]
2023     WorkSafeBC Glutamine for treating concussions
2023     Adelaide Health Technology Assessment (AHTA) Newborn bloodspot screening for sickle cell disease and beta thalassaemia
2023     WorkSafeBC Creatine supplementation for treating concussions
2023     NIHR Health Services and Delivery Research programme Impact of interventions to improve recovery of older adults following planned hospital admission on quality-of-life following discharge: linked-evidence synthesis
2023     NIHR Health Services and Delivery Research programme The effectiveness and acceptability of multimedia information when recruiting children and young people to trials: the TRECA meta-analysis of SWATs
2023     NIHR Health Technology Assessment programme The potential impact of policies and structural interventions in reducing cardiovascular disease and mortality: a systematic review of simulation-based studies
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Dental bridges for partial tooth loss
2023     NIHR Health Services and Delivery Research programme Evaluating mental health decision units in acute care pathways (DECISION): a quasi-experimental, qualitative and health economic evaluation
2023     Penn Medicine Center for Evidence-based Practice (CEP) Mortality review 2023 update
2023     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Evondos® medicine-dispensing service
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of adult patients with chronic immune thrombocytopenia after failure of first-line therapies
2023     NIHR Health Technology Assessment programme Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis
2023     Ontario Health Bariatric surgery for people with class I obesity and poorly controlled type 2 diabetes
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: Cervical cancer: transition from from Pap test screening to HPV testing]
2023     NIHR Health Technology Assessment programme Treatment of Hidradenitis Suppurativa Evaluation Study: the THESEUS prospective cohort study
2023     Ontario Health Testing for homologous recombination deficiency in patients diagnosed with ovarian cancer
2023     Institute for Clinical and Economic Review (ICER) Fezolinetant for moderate to severe vasomotor symptoms associated with menopause: effectiveness and value
2023     NIHR Health Technology Assessment programme Techniques to increase lumbar puncture success in newborn babies: the NeoCLEAR RCT
2023     Ontario Health Wire-free, nonradioactive localization techniques to guide surgical excision of nonpalpable breast cancer tumours
2023     Ontario Health Placental growth factor (PlGF)-based biomarkers for risk prediction in people with suspected preeclampsia
2023     Austrian Institute for Health Technology Assessment (AIHTA) Image-guided spinal injections in the treatment of chronic spinal pain: an overview of evidence-based guideline recommendations and specific focus on guidance techniques
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Robot-assisted rehabilitation for incomplete spinal cord injury]
2023     Institute for Clinical and Economic Review (ICER) Gene therapies for sickle cell disease: effectiveness and value
2023     Austrian Institute for Health Technology Assessment (AIHTA) SMA therapies: mid- to long-term follow-up of spinal muscular atrophy (SMA) patients treated for ≥24 months with nusinersen or onasemnogene abeparvovec and ≥12 months for patients treated with risdiplam or combination therapies
2023     Institute for Clinical and Economic Review (ICER) Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH)
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Strategies for recruitment and programme adherence in group programmes for children, adolescents and adults with overweight and grade 1 obesity]
2023     Institute for Clinical and Economic Review (ICER) Lecanemab for early Alzheimer’s disease
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Myopia control spectacle lenses for children and adolescents]
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of andexanet alfa (Ondexxya)]
2023     Institute for Clinical and Economic Review (ICER) Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Registries in Austria and their utilisation for healthcare improvement]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Autologous fat grafting in osteoarthritis]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Endovenous laser therapy for varicose veins in the lower extremities]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Multigene panel testing for tumors of known origin]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Edaravone in amyotrophic lateral sclerosis]
2023     NIHR Health Technology Assessment programme Views of female genital mutilation survivors, men and health-care professionals on timing of deinfibulation surgery and NHS service provision: qualitative FGM Sister Study
2023     Institute for Clinical and Economic Review (ICER) Value assessment framework
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fibromatoses of the hand (Dupuytren's disease) and / or foot (Ledderhose's disease): do those affected benefit from radiation therapy?]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Flash glucose monitoring system in diabetes mellitus patients]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of coronary sinus narrowing device for the treatment of refractory angina]
2023     Institute for Clinical and Economic Review (ICER) ICER-PHTI assessment framework for digital health technologies
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab in triple-negative breast cancer]
2023     Institute for Clinical and Economic Review (ICER) White bagging, brown bagging, and site of service policies: best practices in addressing provider markup in the commercial insurance market
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Restless legs syndrome: can the symptoms be alleviated through non-medicinal procedures?]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency ablation of parathyroid glands]
2023     Institute for Clinical and Economic Review (ICER) Applying the results of comparative effectiveness research to control drug costs: policy options for California
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Contraception: comparison of hormonal coils and copper coils]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Levonorgestrel-releasing intrauterine device as contraceptive method in women of childbearing age]
2023     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Support for the implementation of new ways of working at the Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale]
2023     Norwegian Institute of Public Health (NIPH) 177Lu-PSMA-617 for treatment of metastatic castration resistant prostate cancer: a health technology assessment
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Evaluation of the lung cancer screening program]
2023     Institute for Clinical and Economic Review (ICER) Advancing health technology assessment methods that support health equity
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Cannabidiol in epilepsy. National versus international products comparison]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Ovarian tissue cryopreservation and transplantation in patients with cancer or benign diseases to fertility preservation]
2023     Institute for Clinical and Economic Review (ICER) Assessment of barriers to fair access
2023     National Evidence-based Healthcare Collaborating Agency (NECA) [Low-level light therapy for primary dysmenorrhea]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [CROS and BICROS hearing aids in unilateral and asymmetric bilateral hearing loss]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Efficacy and safety of Emotional Freedom Techniques for the treatment of anxiety, depression and post traumatic stress disorders]
2023     Penn Medicine Center for Evidence-based Practice (CEP) Effectiveness of communication strategies for patients who are non-vocal due to artificial airways
2023     Health Technology Wales (HTW) Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Medial pivot prosthesis in primary total knee arthroplasty]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Invasive monitoring of pulmonary artery pressure in patients with symptomatic heart failure]
2023     Health Information and Quality Authority (HIQA) Rapid health technology assessment of continuous glucose monitoring in adults with type 1 diabetes mellitus
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Robotic surgery in benign and malignant surgical pathology (urology, general and digestive surgery, cardiothoracic surgery, gynecology, endocrinology, ophthalmology, and head and neck surgery). Chapter I: cardiothoracic, endocrine, ophthalmological surgery, and head and neck surgery]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Multiplex PCR for moderate to severe acute lower respiratory tract infections]